|Bid||63.58 x 800|
|Ask||63.99 x 1800|
|Day's range||62.72 - 63.90|
|52-week range||57.19 - 74.12|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||17.83|
|Earnings date||27 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||2.92 (4.57%)|
|Ex-dividend date||14 Jun 2022|
|1y target est||69.35|
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Gilead Sciences, Inc. (GILD) and CSX Corporation (CSX).
FOSTER CITY, Calif., May 19, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report released by Funders Concerned About AIDS (FCAA). The report, found at: https://www.fcaaids.org/inform/philanthropic-support-to-address-hiv-aids/, is released annually and is widely regarded as the most comprehensive study of its kind. It analyzes 2020 funding data (the most recent year available) revealing
Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.